Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments (Q40883325)

24 September 2017

1 reference

title

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments (English)

1 reference

24 September 2017

Scheen AJ

1

1 reference

24 September 2017

1 September 1997

1 reference

24 September 2017

1 reference

24 September 2017

54

1 reference

24 September 2017

3

1 reference

24 September 2017

355-368

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199754030-00001

24 September 2017

0 references

cites work

Imidazoline compounds stimulate insulin release by inhibition of K(ATP) channels and interaction with the exocytotic machinery

1 reference

12 December 2020

Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials

1 reference

12 December 2020

The fourth musketeer--from Alexandre Dumas to Claude Bernard

1 reference

12 December 2020

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

12 December 2020

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

New treatments for patients with type 2 diabetes mellitus

1 reference

12 December 2020

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family

1 reference

12 December 2020

Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas

1 reference

12 December 2020

Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

1 reference

12 December 2020

Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

12 December 2020

Pharmacological treatment of the obese diabetic patient

1 reference

12 December 2020

Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.

1 reference

12 December 2020

Stepwise and combination drug therapy for the treatment of NIDDM.

1 reference

12 December 2020

1 reference

12 December 2020

Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM

1 reference

12 December 2020

Fluoxetine in the treatment of obese type 2 diabetic patients.

1 reference

12 December 2020

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

1 reference

12 December 2020

Oral hypoglycemic agents

1 reference

12 December 2020

Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management

1 reference

12 December 2020

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

1 reference

12 December 2020

Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years

1 reference

12 December 2020

Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology.

1 reference

12 December 2020

Is metformin safe enough for ageing type 2 diabetic patients?

1 reference

12 December 2020

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

12 December 2020

Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.

1 reference

12 December 2020

Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects

1 reference

12 December 2020

Sulfonylureas in NIDDM.

1 reference

12 December 2020

New Oral Antidiabetic Agents: From Today and Tomorrow. Proceedings of the Hoechst Satellite Symposium to the 15th International Diabetes Federation Congress. Kobe, Japan, 4-5 November 1994

1 reference

12 December 2020

A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients

1 reference

12 December 2020

The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion

1 reference

12 December 2020

Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

1 reference

12 December 2020

Oral antidiabetic drugs: an overview

1 reference

12 December 2020

Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy

1 reference

12 December 2020

Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Management of non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Re-evaluation of a biguanide, metformin: mechanism of action and tolerability

1 reference

12 December 2020

Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss

1 reference

12 December 2020

Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors

1 reference

12 December 2020

[Sulfonylureas: pharmacology and hypoglycemic risk]

1 reference

12 December 2020

Insulin use in NIDDM.

1 reference

12 December 2020

Possible new therapeutic approach in diabetes mellitus by inhibition of carnitine palmitoyltransferase 1 (CPT1)

1 reference

12 December 2020

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

12 December 2020

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

1 reference

12 December 2020

Should we use intensive insulin therapy after oral agent failure in type II diabetes?

1 reference

12 December 2020

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes

1 reference

12 December 2020

Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients

1 reference

12 December 2020

Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies

1 reference

12 December 2020

1 reference

12 December 2020

Weight and non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?

1 reference

12 December 2020

Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.

1 reference

12 December 2020

Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend.

1 reference

12 December 2020

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association

1 reference

12 December 2020

Tumor necrosis factor alpha: a key component of the obesity-diabetes link

1 reference

12 December 2020

Clinical studies with dexfenfluramine: from past to future

1 reference

12 December 2020

1 reference

12 December 2020

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

1 reference

12 December 2020

The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia

1 reference

12 December 2020

Management of Non-Insulin-Dependent Diabetes Mellitus

1 reference

12 December 2020

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

1 reference

12 December 2020

Clinical pharmacokinetics of metformin

1 reference

12 December 2020

Insulin resistance, hyperinsulinemia and diabetes--contribution of benfluorex. Prague, 11 September 1992. Symposium proceedings

1 reference

12 December 2020

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

12 December 2020

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

12 December 2020

Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.

1 reference

12 December 2020

Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects

1 reference

12 December 2020

Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?

1 reference

12 December 2020

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

1 reference

12 December 2020

Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.

1 reference

12 December 2020

A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. European NIDDM Policy Group

1 reference

12 December 2020

Insulin use in NIDDM. Rationale based on pathophysiology of disease

1 reference

12 December 2020

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

12 December 2020

New Pharmacological Approaches to Therapy of NIDDM

1 reference

12 December 2020

Antihyperglycaemic agents. Drug interactions of clinical importance

1 reference

12 December 2020

Insulin and atheroma. 20-yr perspective

1 reference

12 December 2020

Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus

1 reference

12 December 2020

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year

1 reference

12 December 2020

alpha-Glucosidase inhibition by miglitol in NIDDM patients

1 reference

12 December 2020

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity

1 reference

12 December 2020

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

1 reference

12 December 2020

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

12 December 2020

The effect of etomoxir on insulin sensitivity in type 2 diabetic patients

1 reference

12 December 2020

Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus

1 reference

12 December 2020

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

12 December 2020

The insulin-sparing effect of metformin in insulin-treated diabetic patients

1 reference

12 December 2020

Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.

1 reference

12 December 2020

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

12 December 2020

Benfluorex and blood glucose control in non insulin-dependent diabetic patients.

1 reference

12 December 2020

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

1 reference

12 December 2020

Management of the Adult Onset Diabetic with Sulfonylurea Drug Failure

1 reference

12 December 2020

Drugs on the horizon for treatment of type 2 diabetes.

1 reference

12 December 2020

The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.

1 reference

12 December 2020

Improving the action of insulin.

1 reference

12 December 2020

A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus

1 reference

12 December 2020

Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes

1 reference

12 December 2020

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

1 reference

12 December 2020

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

1 reference

12 December 2020

Biguanides and sulfonylureas as combination therapy in NIDDM.

1 reference

12 December 2020

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

1 reference

12 December 2020

Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects

1 reference

12 December 2020

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

12 December 2020

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers

1 reference

12 December 2020

Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes

1 reference

12 December 2020

10.2165/00003495-199754030-00001

Identifiers

DOI

1 reference

PubMed ID

9279500

Dimensions Publication ID

24 September 2017

0 references

1 reference

PubMed ID

9279500